June 17, 2010

Results from Phase III EINSTEIN-DVT Study with Bayer's Rivaroxaban to be Presented at Hot Line Session at ESC 2010

Berlin, Germany, June 17, 2010 - Bayer Schering Pharma, Germany, today
announced that findings from the Phase III EINSTEIN-DVT study will be presented
at the Hot Line Session on August 31, 2010, 11:00-12:30 CET, at the Annual
Meeting of the European Society of Cardiology (ESC) in Stockholm, Sweden, by
lead investigator Harry R. Buller, MD, Academic Medical Center, Amsterdam, the

The multinational Phase III EINSTEIN-DVT study investigated a new single-drug
approach with rivaroxaban compared with standard therapy in a randomized,
open-label, assessor-blind, non-inferiority study involving more than 3,400
patients with acute symptomatic deep vein thrombosis (DVT), but without any
symptoms of pulmonary embolism (PE). Standard therapy for venous
thromboembolism, including DVT, currently includes two compounds: low molecular
weight heparin administered by subcutaneous injection, followed by a vitamin K
antagonist, which requires regular monitoring of the prothrombin time, reported
as the International Normalized Ratio (INR), for safety.

Patients received either oral rivaroxaban or body weight-adjusted enoxaparin
followed by warfarin or acenocoumarol, dose adjusted to maintain a therapeutic
INR (target 2.5, range 2.0-3.0), for 3, 6 or 12 months, based on the
physician's assessment at baseline. The primary efficacy outcome of
EINSTEIN-DVT is the cumulative incidence of symptomatic recurrent venous
thromboembolism (VTE), non-fatal or fatal pulmonary embolism (PE). The
principal safety outcome is the composite of major and clinically relevant
non-major bleeding.

About the EINSTEIN Clinical Trial Program

EINSTEIN is a global clinical development program composed of three clinical
studies in more than 8,000 patients. Two of these studies enrolled patients
with acute, symptomatic deep vein thrombosis (EINSTEIN-DVT) or pulmonary
embolism (EINSTEIN-PE). In these two trials, patients received oral rivaroxaban
15 mg twice-daily for the first three weeks, followed by oral rivaroxaban 20 mg
once-daily, compared with initial enoxaparin treatment followed by a vitamin K

The third study, EINSTEIN-Extension, compared the efficacy and safety of
rivaroxaban to placebo in the secondary prevention of recurrent symptomatic
venous blood clots by extending preventative treatment by 6 or 12 months beyond
a previously completed regimen of 6 or 12 months of therapy, and enrolled
approximately 1,200 patients from 28 countries around the world with
symptomatic DVT or PE. The results of the Phase III EINSTEIN-Extension study
were presented in December 2009 at the 51st Annual Meeting of the American
Society of Hematology (ASH) in New Orleans (USA). The data demonstrated that
rivaroxaban 20 mg once-daily significantly reduced the risk of recurrent
symptomatic venous thromboembolism (VTE) compared to placebo in patients who
had been treated for a previous deep vein thrombosis (DVT) or pulmonary
embolism (PE). The rate of major bleeding was low.

About Rivaroxaban

Rivaroxaban is a novel oral anticoagulant that was invented in Bayer Schering
Pharma's Wuppertal laboratories in Germany, and is being jointly developed by
Bayer HealthCare and Johnson & Johnson Pharmaceutical Research & Development,
L.L.C. In clinical studies, rivaroxaban has been shown to be effective in
preventing VTE in adult patients following elective hip or knee replacement
surgery. It has a rapid onset of action with a predictable dose response and
high bioavailability, no requirement for coagulation monitoring, as well as a
limited potential for food and drug interactions. Rivaroxaban is marketed under
the brand name Xarelto® for VTE prevention in adult patients following elective
hip or knee replacement surgery, and it is the only new oral anticoagulant that
has consistently demonstrated superior efficacy over enoxaparin for this
indication. Xarelto® is approved in more than 100 countries worldwide and has
been successfully launched in more than 75 countries by Bayer Schering Pharma
achieving the market leader position among the new oral anticoagulants.

The extensive clinical trial program supporting rivaroxaban makes it the most
studied oral, direct Factor Xa inhibitor in the world today. More than 65,000
patients are expected to be enrolled into the rivaroxaban clinical development
program, which will evaluate the product in the prevention and treatment of a
broad range of acute and chronic blood-clotting disorders, including stroke
prevention in patients with atrial fibrillation, secondary prevention of acute
coronary syndrome, and VTE prevention in hospitalized, medically ill patients.

To learn more about thrombosis, please visit www.thrombosisadviser.com.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of
healthcare, nutrition and high-tech materials. Bayer HealthCare, a subsidiary
of Bayer AG, is one of the world's leading, innovative companies in the
healthcare and medical products industry and is based in Leverkusen, Germany.
The company combines the global activities of the Animal Health, Bayer Schering
Pharma, Consumer Care and Medical Care divisions. Bayer HealthCare's aim is to
discover, manufacture and market products that will improve human and animal
health worldwide. Find more information at www.bayerhealthcare.com.

About Bayer Schering Pharma

Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company.
Its research and business activities are focused on the following areas:
Diagnostic Imaging, General Medicine, Specialty Medicine and Women's
Healthcare. With innovative products, Bayer Schering Pharma aims for leading
positions in specialized markets worldwide. Using new ideas, Bayer Schering
Pharma aims to make a contribution to medical progress and strives to improve
the quality of life. Find more information at www.bayerscheringpharma.de.

Forward-looking statements

This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management. Various
known and unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation, development
or performance of the company and the estimates given here. These factors
include those discussed in Bayer's public reports which are available on the
Bayer website at www.bayer.com. The company assumes no liability whatsoever to
update these forward-looking statements or to conform them to future events or